Nicotinic acid mononucleotide

Name: Nicotinic acid mononucleotide
Brand: MedChemExpress
SKU: HY-128700
Rating: 4.5 (1 reviews)

Cat. No.: HY-128700 Purity: 98.08%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Nicotinic acid mononucleotide acts as a SARM1 inhibitor and a NAD⁺ biosynthesis intermediate, with an IC₅₀ value of 93.3 μM against SARM1. Nicotinic acid mononucleotide exerts axon-protective effects, delays axonal degeneration, elevates NAD⁺ levels, enhances Sirt1 activity, improves myocardial capillary density and alleviates myocardial fibrosis. Nicotinic acid mononucleotide reverses diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD⁺ levels. Nicotinic acid mononucleotide is applicable to research related to cancer, multiple sclerosis, diabetic cardiomyopathy, neurodegenerative diseases and Huntington's disease.

For research use only. We do not sell to patients.

Nicotinic acid mononucleotide Chemical Structure

CAS No. : 321-02-8

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in Water ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in Water	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Nicotinic acid mononucleotide:

Nicotinic acid mononucleotide triethylamine In-stock

1 Publications Citing Use of MCE Nicotinic acid mononucleotide

•Diabetes Res Clin Pract. 2023 Dec:206:111014. [Abstract]

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Endogenous Metabolite Isoform Specific Products:

View All Isoforms

Human Endogenous Metabolite Microbial Metabolite

View All Sirtuin Isoform Specific Products:

View All Isoforms

Sirtuin SIRT1 SIRT2 SIRT3 SIRT6 SIRT5 SIRT7 SIRT4

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Nicotinic acid mononucleotide (0-250 μM; assay duration) inhibits the NAD⁺ hydrolase activity of full-length human SARM1 by binding to its N-terminal ARM domain; its IC₅₀ is 93.3 μM in the absence of NMN, while this inhibitory effect is attenuated in the presence of 5 μM NMN (IC₅₀ = 147.2 μM)^[1].
Nicotinic acid mononucleotide delays axonal degeneration of mammalian axons by restoring reduced intracellular NAD⁺ levels^[3].
Nicotinic acid mononucleotide (NAM) increases the expression of Sirt1 and the phosphorylation level of eNOS in human umbilical vein endothelial cells (HUVECs) treated with high glucose^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Nicotinic acid mononucleotide (NAM) (400 mg/kg/day; i.p.; daily; 8 weeks) partially reverses streptozotocin (HY-13753)-induced diabetic cardiomyopathy in diabetic mice by increasing myocardial NAD⁺ levels, improving cardiac function and ultrastructure, enhancing capillary density, alleviating fibrosis, and restoring Sirt1 expression^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6J (8-week-old male; streptozotocin-induced diabetic)^[4]
Dosage:	400 mg/kg/day
Administration:	i.p.; daily; 8 weeks
Result:	Partially increased myocardial NAD+ levels in diabetic mice. Partially reversed impaired left ventricular ejection fraction (LVEF) and fractional shortening (FS) relative to untreated diabetic mice. Improved myocardial ultrastructural abnormalities (reduced Z-line misalignment, mitochondrial swelling, and myofibril disorganization). Increased myocardial capillary density relative to untreated diabetic mice. Reduced myocardial expression of fibrosis markers TGF-β1 and collagen I relative to untreated diabetic mice. Restored myocardial Sirt1 mRNA and protein expression relative to untreated diabetic mice. Had no effect on blood glucose or body weight in diabetic mice, and no significant effect on interventricular septal thickness (IVSD) or left ventricular posterior wall thickness (LVPWD).

Molecular Weight

335.20

Formula

C₁₁H₁₄NO₉P

CAS No.

321-02-8

Appearance

Solid

Color

White to off-white

SMILES

O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1[N+]2=CC=CC(C([O-])=O)=C2

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

H₂O : 10 mg/mL (29.83 mM; Need ultrasonic)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.9833 mL	14.9165 mL	29.8329 mL
5 mM	0.5967 mL	2.9833 mL	5.9666 mL
10 mM	0.2983 mL	1.4916 mL	2.9833 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 98.08%

Select Batch:

Data Sheet (280 KB) SDS (252 KB)

COA (249 KB) HNMR (275 KB) CNMR (248 KB) LCMS (88 KB)

Handling Instructions (2659 KB)

References

[1]. Sasaki Y, et al. Nicotinic acid mononucleotide is an allosteric SARM1 inhibitor promoting axonal protection. Exp Neurol. 2021;345:113842. [Content Brief]

[2]. O'Hara JK, et al. Targeting NAD+ metabolism in the human malaria parasite Plasmodium falciparum. PLoS One. 2014;9(4):e94061. Published 2014 Apr 18. [Content Brief]

[3]. Khan JA, et al. Nicotinamide adenine dinucleotide metabolism as an attractive target for drug discovery. Expert Opin Ther Targets. 2007;11(5):695-705. [Content Brief]

[4]. Zeng F, et al. ACMSD mediated de novo NAD⁺ biosynthetic impairment in cardiac endothelial cells as a potential therapeutic target for diabetic cardiomyopathy. Diabetes Res Clin Pract. 2023;206:111014. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

H₂O	1 mM	2.9833 mL	14.9165 mL	29.8329 mL	74.5823 mL
	5 mM	0.5967 mL	2.9833 mL	5.9666 mL	14.9165 mL
	10 mM	0.2983 mL	1.4916 mL	2.9833 mL	7.4582 mL
	15 mM	0.1989 mL	0.9944 mL	1.9889 mL	4.9722 mL
	20 mM	0.1492 mL	0.7458 mL	1.4916 mL	3.7291 mL
	25 mM	0.1193 mL	0.5967 mL	1.1933 mL	2.9833 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.